Ann: Admedus achieves label expansion for CardioCel in Europe, page-26

Increase in centre numbers is fantastic and bodes well for the future.
However centre no.s does not equate to ongoing sales.
I think Stonemason alluded to the difficulty in maintaining market share a few days ago.
I believe many surgeons implant the product and then monitor those patients over a period of time before making it automatic product of choice.
So the increase in centres probably maintains the status quo of present sales but there could be a lag before all centres use CC on an ongoing basis.
I don't know how long the surgeons will do in house clinical trials before they have confidence in the product. Apparently they have often been burnt with inferior products and consequently are very cautious.